Tobramycin safety and efficacy review article
Copyright © 2022. Published by Elsevier Ltd..
Pseudomonas aeruginosa is a common respiratory pathogen found in patients with cystic fibrosis (CF), contributing to increased hospitalization, more rapid progression of CF lung disease, and increased risk of death. Guidelines recommend early therapy using tobramycin inhaled solution (TIS) or inhaled powder (TIP). Both TIS and TIP treatment regimens have demonstrated positive clinical outcomes in efficacy and safety, including improvements in FEV1, decreased sputum P. aeruginosa density, decreased rates in antipseudomonal antibiotic use, and reduced rates of hospitalizations due to respiratory events. In a comparison of patient preference for TIS versus TIP, a patient survey cited time savings and convenience as preferences for TIP. However, both TIP and TIS offer advantages that may benefit patients and increase treatment adherence depending on patient circumstances. TIS may be suitable for younger patients at home where parents and caregivers may better control proper administration, older individuals, and those with low FEV1. Dry powder inhalers are suitable when patients have less time to commit to their self-care (eg, patients who work, are remotely located, return home late, or are on vacation), and can reduce the patient treatment burden compared with nebulized delivery. In this expert review, we summarize the available data on tobramycin regarding its molecular characteristics, mechanism of action, and efficacy and safety for the treatment of acute and chronic P. aeruginosa infection.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:195 |
|---|---|
| Enthalten in: |
Respiratory medicine - 195(2022) vom: 25. Apr., Seite 106778 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schwarz, Carsten [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-Bacterial Agents |
|---|
| Anmerkungen: |
Date Completed 31.03.2022 Date Revised 01.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.rmed.2022.106778 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337808511 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337808511 | ||
| 003 | DE-627 | ||
| 005 | 20231225235244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.rmed.2022.106778 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1125.xml |
| 035 | |a (DE-627)NLM337808511 | ||
| 035 | |a (NLM)35249787 | ||
| 035 | |a (PII)S0954-6111(22)00043-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schwarz, Carsten |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tobramycin safety and efficacy review article |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2022 | ||
| 500 | |a Date Revised 01.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier Ltd. | ||
| 520 | |a Pseudomonas aeruginosa is a common respiratory pathogen found in patients with cystic fibrosis (CF), contributing to increased hospitalization, more rapid progression of CF lung disease, and increased risk of death. Guidelines recommend early therapy using tobramycin inhaled solution (TIS) or inhaled powder (TIP). Both TIS and TIP treatment regimens have demonstrated positive clinical outcomes in efficacy and safety, including improvements in FEV1, decreased sputum P. aeruginosa density, decreased rates in antipseudomonal antibiotic use, and reduced rates of hospitalizations due to respiratory events. In a comparison of patient preference for TIS versus TIP, a patient survey cited time savings and convenience as preferences for TIP. However, both TIP and TIS offer advantages that may benefit patients and increase treatment adherence depending on patient circumstances. TIS may be suitable for younger patients at home where parents and caregivers may better control proper administration, older individuals, and those with low FEV1. Dry powder inhalers are suitable when patients have less time to commit to their self-care (eg, patients who work, are remotely located, return home late, or are on vacation), and can reduce the patient treatment burden compared with nebulized delivery. In this expert review, we summarize the available data on tobramycin regarding its molecular characteristics, mechanism of action, and efficacy and safety for the treatment of acute and chronic P. aeruginosa infection | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cystic fibrosis | |
| 650 | 4 | |a FEV(1) | |
| 650 | 4 | |a Hospitalizations | |
| 650 | 4 | |a Pseudomonas aeruginosa | |
| 650 | 4 | |a Sputum density | |
| 650 | 4 | |a Tobramycin | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Tobramycin |2 NLM | |
| 650 | 7 | |a VZ8RRZ51VK |2 NLM | |
| 700 | 1 | |a Taccetti, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Burgel, Pierre-Regis |e verfasserin |4 aut | |
| 700 | 1 | |a Mulrennan, Siobhain |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory medicine |d 1993 |g 195(2022) vom: 25. Apr., Seite 106778 |w (DE-627)NLM012605247 |x 1532-3064 |7 nnns |
| 773 | 1 | 8 | |g volume:195 |g year:2022 |g day:25 |g month:04 |g pages:106778 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.rmed.2022.106778 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 195 |j 2022 |b 25 |c 04 |h 106778 | ||